To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.
X

New Type of Drug Discovery Isogenic Cell Models Created by CRISPR Genome Editing

Angio-Ready™: An improved in vitro model of angiogenesis

Angiogenesis is a multi-step physiological process that is involved in a large number of normal and disease state processes. In this webinar, we will introduce the Angio-Ready™ Angiogenesis Assay System, an in vitro co-culture system for measuring angiogenesis. Angio-Ready™ consists of an assay-ready mixture of an hTERT-immortalized human aortic endothelial cell line (TeloHAEC-GFP) and an hTERT-immortalized adipose-derived mesenchymal stem cell line (hTERT-MSC) in a specially formulated medium. Both cell lines have been well-characterized to verify that they retain the most important characteristic of their parental counterparts. The new co-culture system forms functional tubular structures in less than 7 days and responds appropriately in a dose dependent manner to known agonists and inhibitors of angiogenesis. Thus, Angio-Ready™ is a ready-to-use, time-saving, high-throughput model for screening drugs or biomolecules for their effect on angiogenesis in cancer, toxicology, diabetes, cardiovascular disease, wound healing, and other pathologies.